Here is how fenbendazole compares to other benzimidazoles (like mebendazole, albendazole, flubendazole, and thiabendazole) for brain cancer:

In Vitro Efficacy and Mechanisms. In laboratory cell cultures, fenbendazole, mebendazole, and flubendazole all demonstrate highly potent and comparable efficacy against human glioblastoma cell lines (such as U87 and U251).

• Potency: All three drugs effectively inhibit brain cancer cell proliferation at extremely low concentrations, with IC50 values generally between 0.1 and 0.3 μM. Another approved drug in this class, thiabendazole, also inhibits GBM cell proliferation and invasion but requires significantly higher concentrations (160–455 μM) to achieve the same effect.

• Shared Mechanisms: Fenbendazole, mebendazole, and flubendazole utilize the same primary mechanisms against brain cancer. They disrupt microtubule formation, arrest the cancer cell cycle at the G2/M phase, and induce concurrent apoptosis and pyroptosis (a highly inflammatory form of cell death).

Blood-Brain Barrier Penetration and In Vivo Efficacy. While fenbendazole successfully blocked brain tumor engraftment in mice, researchers rapidly shifted their focus to mebendazole and albendazole for advanced in vivo testing. This shift occurred because mebendazole and albendazole are already FDA-approved for humans and have a proven ability to cross the blood-brain barrier, as they are clinically used to treat parasitic infections that invade the central nervous system (like neurocysticercosis).

• Mebendazole vs. Albendazole: In direct comparative animal studies of glioblastoma, mebendazole emerged as the clear frontrunner. Mebendazole significantly extended mean survival times in mouse glioma models (by up to 63%), whereas albendazole failed to extend survival in the same models.

• Flubendazole: Flubendazole has also shown strong in vivo efficacy, successfully suppressing tumor growth in nude mouse GBM xenograft models without causing obvious adverse effects.

Clinical Translation Because of its superior preclinical performance, established human safety profile, and known ability to penetrate brain tissue (particularly through a specific formulation known as “Polymorph C”), mebendazole is the primary benzimidazole that has advanced into formal neuro-oncology clinical trials.

Currently, mebendazole is being actively evaluated in Phase I and II clinical trials for newly diagnosed and recurrent pediatric brain tumors (such as medulloblastomas and high-grade gliomas) as well as adult glioblastomas, often in combination with standard radiation and temozolomide chemotherapy. In contrast, because it is strictly a veterinary medication, there are currently no formal clinical trials evaluating fenbendazole for human brain cancer, and its use in humans remains limited to preclinical testing and anecdotal self-administration.

Part Two examines the current research and evidence, including laboratory studies, animal research, and limited human data. I present both the promising findings and the significant limitations.

Part Three offers practical guidance for patients considering fenbendazole—how to research it further, questions to ask your doctors, how it’s obtained and used, dosing protocols being discussed, potential side effects, and how to monitor your response.

Part Four explores real-world experiences through case studies and patient stories, helping you understand how others have approached this decision.

Part Five provides critical analysis—the concerns, the unknowns, the reasons for caution, and the importance of maintaining realistic expectations.

Part Six looks at the bigger picture—the regulatory landscape, the economics of drug repurposing, and what the fenbendazole story tells us about cancer treatment and patient empowerment.

Get the book on Amazon.

Upregulation and Activation of p53: Fenbendazole significantly upregulates the expression of the wild-type p53 tumor suppressor protein and promotes its translocation to the mitochondria.

Downregulation of Glycolytic Targets: Once activated, the p53 signaling pathway acts as a switch to suppress aerobic glycolysis, also known as the Warburg effect. It specifically downregulates the expression of glucose transporters (such as GLUT1) to prevent glucose from entering the cell, and strongly inhibits the expression of hexokinase 2 (HK2), the first critical enzyme in the glycolytic pathway.

Metabolic Starvation: By impeding these specific targets, fenbendazole drastically reduces the cancer cell’s glucose consumption, limits lactate production, and depletes intracellular ATP levels, effectively starving the tumor of energy.

Experimental Confirmation: The direct molecular link between p53 and this metabolic disruption was confirmed in laboratory studies in which knockdown of p53 in cancer cells partially reversed fenbendazole’s ability to inhibit HK2 expression, reduce glucose consumption, and deplete ATP.

Ultimately, by targeting the p53-glycolysis axis with HK2 as the primary downstream effector, fenbendazole pushes cancer cells into an energetic crisis. This starvation acts as the molecular trigger that executes terminal cell death mechanisms, including apoptosis and the highly inflammatory pyroptosis discussed earlier.

Here is how fenbendazole triggers pyroptosis in these different contexts:

1. The HK2/Caspase-3/GSDME Pathway (Observed in Breast Cancer) In breast cancer models, fenbendazole links metabolic disruption directly to pyroptotic cell death by targeting the tumor’s energy metabolism.

• Inhibition of Glycolysis (HK2 Downregulation): FBZ interacts with the p53 signaling pathway to significantly suppress the expression of hexokinase 2 (HK2), a critical enzyme required for aerobic glycolysis (the Warburg effect).

• Activation of the BAX/Caspase-3 Cascade: The inhibition of HK2 acts as a trigger that upregulates the pro-apoptotic protein BAX, which subsequently activates the executioner enzyme caspase-3.

• Cleavage of GSDME: While caspase-3 is traditionally associated with silent apoptosis, in cells expressing the protein Gasdermin E (GSDME), activated caspase-3 cleaves GSDME into its active N-terminal fragment (GSDME-NT).

• Pore Formation and Cell Lysis: The GSDME-NT fragments oligomerize and insert themselves into the cancer cell’s plasma membrane, forming pores. This rapidly causes the cancer cells to swell, form large balloon-like membrane blisters, and burst, releasing their intracellular contents, including lactate dehydrogenase (LDH) and highly inflammatory cytokines like IL-1β and IL-18 into the tumor microenvironment.

2. The NF-κB/NLRP3/GSDMD Pathway (Observed in Glioblastoma) In human glioblastoma cells, fenbendazole (along with other benzimidazoles like mebendazole and flubendazole) utilizes a different gasdermin protein and inflammasome pathway to execute pyroptosis.

• NF-κB Nuclear Translocation: FBZ treatment promotes the translocation of the NF-κB transcription factor from the cytosol to the nucleus.

• Inflammasome Activation: The activation of NF-κB drives the expression and assembly of the NLRP3 inflammasome.

• Caspase-1 Activation and GSDMD Cleavage: The NLRP3 inflammasome recruits and activates caspase-1. Activated caspase-1 then cleaves a different gasdermin protein, Gasdermin D (GSDMD), to generate an active N-terminal fragment (GSDMD-N).

• Pore Formation and Cytokine Release: Similar to GSDME, the newly formed GSDMD-N fragments insert into the plasma membrane to create pores. This ruptures the glioblastoma cells and triggers the massive release of LDH, IL-1β, and IL-18.

In both mechanisms, fenbendazole effectively shifts the cancer cell’s fate from non-inflammatory death (apoptosis) to highly inflammatory death (pyroptosis), which not only kills the cancer cell but also alters the tumor microenvironment by releasing immune-stimulating signals.

Here is a comparison of the two drugs based on the available research:

Regulatory Status and Human Clinical Evidence

• Approval for Human Use: The most crucial difference is that mebendazole is FDA-approved for human use, possessing a decades-long track record of safety and tolerability in humans. In contrast, fenbendazole is strictly approved for veterinary use and is not regulated by the FDA or EMA for humans.

• Clinical Trials: Because of its established human safety profile, MBZ has advanced into formal Phase I and II clinical trials for various human cancers, including pediatric and adult gliomas, and advanced gastrointestinal cancers. Conversely, there are currently no active, registered clinical trials evaluating fenbendazole in humans; its use in human cancer is primarily driven by preclinical studies and anecdotal social media reports, such as the viral “Joe Tippens” case.

Mechanisms of Action and Efficacy

• Microtubule Disruption: Both drugs effectively kill cancer cells by acting as microtubule-destabilizing agents. They bind to tubulin, preventing it from polymerizing, which arrests the cancer cell cycle at the G2/M phase and induces apoptosis (cell death).

• Metabolic Disruption (FBZ’s Unique Advantage): While both drugs are effective, some researchers suggest that fenbendazole may surpass mebendazole as the preferred benzimidazole for treating drug-resistant cancer cells. This is because FBZ exhibits a profound ability to disrupt cancer energy metabolism by inhibiting aerobic glycolysis. It down-regulates glucose transporters (GLUT) and impedes hexokinase II (HKII), starving cancer cells of glucose and preventing the buildup of lactate. This mechanism allows FBZ to successfully target cancer cells that are highly resistant to standard chemotherapies, such as 5-fluorouracil-resistant colorectal cancer and taxane-resistant prostate cancer.

• Immunomodulation and Brain Penetration (MBZ’s Advantage): Mebendazole has been noted for its ability to penetrate the blood-brain barrier—particularly its “Polymorph C” formulation—making it highly effective in preclinical models of glioblastoma and medulloblastoma. Additionally, MBZ has been found to act as an immunomodulating agent, helping to switch tumor-promoting M2 macrophages into tumor-inhibiting M1 phenotypes.

Pharmacokinetics and Bioavailability Both drugs suffer from extremely poor water solubility and low oral bioavailability, meaning only a small fraction of an oral dose reaches the bloodstream. To combat this, researchers are developing specific polymorphs for MBZ, while investigating experimental vehicles for FBZ, such as poly-lactic-co-glycolic acid (PLGA) nanoparticles, cyclodextrins, and DMSO formulations, to improve its systemic absorption.

Safety and Toxicity

• MBZ: In human clinical trials for cancer, mebendazole has been shown to be well-tolerated at high doses, with side effects generally limited to mild gastrointestinal upset, transiently elevated liver enzymes, or occasional low blood counts (neutropenia).

• FBZ: While generally safe and well-tolerated in animal species, the off-label self-administration of fenbendazole by human cancer patients has been linked to cases of severe, though reversible, drug-induced liver injury (hepatotoxicity). Due to these risks, medical organizations emphasize relying on evidence-based therapies and formal trials of human-approved drugs like mebendazole rather than self-medicating with veterinary agents.

Link to Paper

Fenbendazole Can Cure Cancer

Case Report: Glioblastoma Multiforme, Male, age 61 and a 34-Day Miracle

Fenbendazole Can Cure Cancer presents Case Reports of people who have treated their own cancers along with other articles to help understand how fenbendazole works to treat cancer. Previous articles covering other cancers are in the Archives link…

Read more

a month ago · 157 likes · 69 comments · Ben Fen

April 27, 2026

Fenbendazole Can Cure Cancer presents Case Reports of people who have treated their own cancers, along with other articles to help understand how fenbendazole works to treat cancer. Previous articles covering other cancers are in the Archives link.

Glioblastoma multiforme (GBM) is the most common and most aggressive primary malignant brain tumor in adults, accounting for roughly half of all primary malignant brain tumors diagnosed each year (Nahm et al., 2023; StatPearls, 2024). Its infiltrative architecture makes complete surgical removal biologically impossible, and its heterogeneous tumor microenvironment — marked by high mutational burden, immune privilege, and abundant vascular endothelial growth factor expression — has defeated virtually every novel therapeutic strategy attempted over the past half-century (StatPearls, 2024; Supple, 2026).

The gold-standard treatment regimen — maximal safe surgical resection followed by concurrent temozolomide chemotherapy and fractionated radiotherapy (the Stupp protocol), with bevacizumab reserved for recurrent disease — has yielded a median overall survival of approximately 15 months in clinical trial populations and roughly 11 months in real-world practice (Fekete et al., 2023; Nahm et al., 2023). Recurrence is not a risk — it is a near-certainty, typically occurring within six to nine months of initial treatment. Once disease recurs, the median survival from progression is just three to nine months, and subsequent treatment options yield rapidly diminishing returns (Nahm et al., 2023).

For these reasons, GBM has been called the “emperor of all cancers” — a term earned not by its frequency but by its near-total defiance of medical intervention. It is against this backdrop that the case of SM must be understood. What follows is not a statistical outlier in a spreadsheet; it is a man who rebuilt his garden, attended his son’s wedding, and is still casting a fishing line — two years after his oncologist had no more treatments to offer.

Case Report

PERSONAL PROFILE

SM is a sixty-one-year-old male at the time of initial diagnosis, a self-described “country boy” whose avocations — hunting, fishing, and gardening — required the physical and cognitive capacity that GBM would systematically strip from him before fenbendazole intervened. His case was reported to this publication by his sister, MM, who served as the architect of his adjunctive treatment strategy.

INITIAL PRESENTATION AND DIAGNOSIS

In February 2023, SM received a confirmed diagnosis of glioblastoma multiforme. Comprehensive multimodal imaging — including PET, CT, and MRI — delineated the tumor burden, and the diagnosis was confirmed histopathologically by biopsy of tissue resected during urgent neurosurgical debulking. Following recovery, SM entered the standard-of-care pathway, receiving bevacizumab (Avastin) and a full course of fractionated cranial radiation therapy.

RECURRENCE: SEPTEMBER 7, 2023

Seven months after diagnosis — precisely within the expected window of recurrence — SM’s GBM returned with what his sister described as cauliflower-like proliferation throughout the brain. The clinical consequences were severe: SM lost motor function on his left side, rendering him unable to perform basic activities of daily living, including dressing himself. His oncologist, faced with a rapidly progressing recurrent GBM in a patient already on bevacizumab, had no curative options to offer. The prognosis at this juncture was weeks to months. SM’s own assessment was stark: “I have nothing to lose — I’ll be dead in a month.”

INITIATION OF FENBENDAZOLE PROTOCOL:
SEPTEMBER 14, 2023

One week after his devastating recurrence was confirmed, MM persuaded SM to begin an adjunctive fenbendazole-based regimen. The complete protocol is detailed below:

RESPONSE: OCTOBER 18, 2023 — THIRTY-FOUR DAYS LATER

The MRI obtained thirty-four days after fenbendazole initiation delivered results that stunned the treating team. All newly formed tumor manifestations had disappeared. The original, established tumor mass was visibly necrosing — dying from within. The rapidity and completeness of this response, occurring within a single month in a patient whose cancer had been progressing aggressively on bevacizumab, points unambiguously to the adjunctive protocol — and most specifically to fenbendazole — as the decisive intervention.

SUSTAINED REMISSION AND QUALITY OF LIFE:
DECEMBER 2024

One year after initiating fenbendazole, SM’s oncologist — a physician who candidly acknowledged he had never before produced a comparable outcome in a GBM patient — declared SM “cancer-free for all intents and purposes.” This assessment was rendered more striking by the oncologist’s acknowledgment that conventional chemotherapy would typically have left a patient in SM’s situation severely debilitated and unable to live independently. Instead, SM was driving, hunting, fishing, and gardening. Of the approximately fifty GBM patients who had been diagnosed alongside SM in 2023, he was, by this point, the sole survivor.

OFFICIAL CONFIRMATION: MAY 8, 2025

SM’s status as essentially cancer-free was formally confirmed on May 8, 2025 — approximately twenty-seven months after initial diagnosis, and nearly twenty months after a recurrence his oncologist could offer nothing further to treat.

UPDATE: APRIL 26, 2026

In a communication received yesterday, MM provided the following update. Following sustained improvement, SM faced pressure from his medical team to undergo another round of low-dose chemotherapy. An MRI performed shortly thereafter showed apparent tumor burden, and a new oncologist delivered the grim assessment that the brain was full of tumors and recommended comfort care only. This proved to be a misdiagnosis: the imaging findings were subsequently attributed to treatment-related cerebral swelling (pseudoprogression), not true recurrence. After several months of recovery from this episode, SM was again confirmed as cancer-free. He attended his son’s wedding on December 20, 2025. He continues to drive, fish, and hunt, and is preparing to start his garden. He remains on continuous IV bevacizumab and the fenbendazole protocol; he experiences fatigue following bevacizumab infusions but maintains independent function and an excellent quality of life.

Discussion

The case of SM presents a constellation of features that, individually, are each extraordinarily uncommon in GBM — and their simultaneous occurrence in a single patient strains any explanation that does not include the fenbendazole protocol.

First, consider the baseline trajectory. Recurrent GBM following bevacizumab — which SM had already been receiving — carries a median post-progression overall survival of approximately 3.4 to 3.8 months (Ellingson et al., 2017). SM’s oncologist’s candid admission that he had never generated a comparable success story in this disease, and that his GBM patients routinely succumbed before further treatment was possible, corroborates this statistical reality at the individual clinical level.

Second, consider the temporal relationship. SM’s cancer was progressing on bevacizumab and radiation. Fenbendazole was introduced on September 14, 2023. Thirty-four days later, all new tumors had vanished and the original mass was necrosing. Bevacizumab was the only constant between the two imaging studies; it was already failing. The introduction of fenbendazole — and the accompanying cimetidine, AHCC, and curcumin — is the only variable that changed in the interval between radiographic catastrophe and radiographic remission.

Third, consider the mechanism-outcome alignment. GBM is defined by rapid cell division, aggressive glucose metabolism (Warburg effect), and evasion of immune surveillance. Fenbendazole directly attacks all three: it arrests mitosis via tubulin disruption, starves tumors by suppressing GLUT transporters and HKII, and its companion cimetidine actively restores suppressed immune function and blocks VEGF-mediated angiogenesis. The observed necrosing pattern — tumors dying from within — is precisely consistent with the metabolic starvation and apoptotic cascade that the biochemical literature predicts.

The April 2026 pseudoprogression episode deserves specific comment because it illustrates a critical danger that families and patients must understand. Treatment-related imaging changes — swelling and inflammation that mimic tumor on MRI — are well-documented in GBM following chemotherapy and radiation. A new oncologist unfamiliar with SM’s full history interpreted these changes as frank recurrence and recommended hospice. Had MM and SM not maintained their resolve and sought clarification, a SM might have abandoned his highly effective protocol based on a misread scan. This episode reinforces that imaging findings in GBM patients on aggressive multimodal therapy must always be interpreted in full clinical context, with pseudoprogression as a leading differential, before any therapeutic surrender is contemplated.

Finally, MM’s report that SM’s experience has contributed to six additional individuals achieving cancer-free status underscores the network effect of these case reports. Knowledge shared freely — without institutional gatekeeping, without the requirement for a pharmaceutical sponsor’s approval — saves lives. That is why this publication exists.

Conclusion

GBM kills virtually everyone it touches, and it kills them quickly. SM had every actuarial reason to be dead within a month of his September 2023 recurrence (today is April 27, 2026). The science of benzimidazoles in brain tumors predicted that fenbendazole could work; the clinical record of SM confirms that it did. His oncologist had never seen anything like it. His original patient cohort of approximately fifty people is gone. He is tending his garden in the spring of 2026.

Of course fenbendazole isn’t a guaranteed cure for every instance of GBM or any other cancer in all situations but there is no reason to not include it in any treatment regimen; standard of care or alternative. What the data in SMs case plainly show: that a 34-day interval separated progressive, treatment-refractory GBM from complete tumor necrosis, and that the only substantive change in that interval was the initiation of fenbendazole and its companion agents. The scientific literature tells us exactly how and why that could happen. This case tells us that it did.

We extend our deepest gratitude to MM for her courage, her diligence, and her generosity in sharing this story. And to SM — a country boy who was willing to take a chance on dog dewormer when every other door had closed — we say: keep fishing.

The following is a deeper dive exploration of the potential explanation of the synergistic effect of fenbendazole on the Avastin glioblastoma treatments that SM received.

• Inhibiting glycolysis

• Down-regulating glucose uptake

• Inducing oxidative stress

• Enhancing apoptosis in cancer cells

• May not be affected by drug resistance

• Lower toxicity

‘In vitro’ studies are tests done in a lab and use cells, tissues, or isolated organs instead of living animals or people.

• Fenbendazole starves the cancer cells of energy by interfering with glucose metabolism.

• It prevents cancer cells from dividing by disrupting the cells’ microtubule formation.

• It activates tumor-suppressor pathways, including the p53 gene, which plays a vital role in maintaining genomic stability and preventing cancer development. (The covid-19 vaccine suppressed the p53 gene)

Fenbendazole has been shown to target certain cancer cells and be less toxic to surrounding healthy tissues. The drug presents a lower level of toxicity compared to other cancer treatment options, and under proper supervision, can be used alongside conventional cancer treatments. Fenbendazole has demonstrated efficacy against chemotherapy-resistant cancer cells and has shown potential to overcome drug resistance.

While fenbendazole was initially formulated for veterinary use, preliminary research suggests that fenbendazole may inhibit cancer cell growth and induce cancer cell death through various mechanisms, such as disruption of microtubule formation and inhibition of glucose uptake. * https://www.healthline.com/health/pancreatic-cancer/fenbendazole-for-pancreatic-cancer

Fenbendazole has been identified as a critical component in targeting cancer’s metabolic vulnerabilities. Due to its ability to destabilize microtubules, fenbendazole demonstrates strong potential as an anticancer agent. By inhibiting tubulin polymerization, fenbendazole constitutes a vital element in disrupting cancer cell division. Additionally, the drug functions synergistically alongside traditional cancer treatment such as chemotherapy.

A 2020 study at Stanford University examined the use of fenbendazole as an adjunct therapy for enhancing anti-cancer effects in cancer patients. The University’s results indicated that fenbendazole may improve treatment outcomes, including reducing tumor size and enhancing the effectiveness of conventional chemotherapy. The inclusion of low-cost fenbendazole in patient treatments improved efficacy, reduced tumor size, reduced toxic side effects, and improved patient treatment outcomes. *Chiang RS, Syed AB, Wright JL, Montgomery B, Srinivas S (2021) Fenbendazole Enhancing Anti-Tumor Effect: A Case Series. Clin Oncol Case Rep 4:2

Preclinical Studies on Fenbendazole and Cancer

Most of the research on Fenbendazole and its anticancer potential has been conducted in preclinical studies, meaning experiments on cell cultures and animal models. While these studies have shown some promising results, it is important for us all to understand that preclinical data doesn’t always translate to human success.

Unlike Fenbendazole, Mebendazole, and Albendazole—all from the Benzimidazole family—have been tested in several clinical trials with cancer patients. *Fenbendazole For Cancer: Research, Trials & Potential https://healnavigator.com/blog/fenbendazole-cancer-clinical-trials/

Preclinical studies demonstrate how fenbendazole disrupts cancer cell growth. However, the lack of medical oversight and proper dosing guidelines may increase the possibility of drug interaction and liver toxicity. These are two factors that should be monitored during any fenbendazole protocol. Monitored patients’ reports indicate that fenbendazole has low toxicity and confirmed therapeutic efficacy in cancer care.

As cancer diagnoses rise globally, the urgency for innovative, effective, and supportive therapies grows stronger. A recent peer-reviewed study has highlighted a groundbreaking protocol combining ivermectin, Fenbendazole, and natural compounds such as Vitamin E, curcumin, and CBD. These elements, when used together, demonstrate significant potential in supporting cancer care. *Low-Toxin BioEnergetic Forum, Alleged Cancer Cure https://lowtoxinforum.com/threads/alleged-cancer-cure.27459/page-4

Drug repositioning is a strategy for identifying new antitumor drugs; it allows existing, approved clinical drugs to be repurposed to treat tumors. Based on the similarities between parasitic diseases and cancer, recent studies aimed to investigate the efficacy of existing antiparasitic drugs in cancer. *Li YQ, Zheng Z, Liu QX, et al. Repositioning of Antiparasitic Drugs for Tumor Treatment. Front Oncol. 2021;11:670804. Published 2021 Apr 29. doi:10.3389/fonc.2021.670804 https://pmc.ncbi.nlm.nih.gov/articles/PMC8117216/

Various studies in cell lines and animals have demonstrated the efficacy of fenbendazole in inhibiting tumor growth and targeting drug-resistant cancer cells by inhibiting glycolysis. *https://ar.iiarjournals.org/content/anticanres/44/9/3725.full.pdf

Despite the lack of regulatory approval and extensive clinical trials for fenbendazole as a cancer treatment in humans, some cancer patients have self-administered the drug, as documented in case studies. Table IV discusses four case reports where fenbendazole has led to a reduction in tumor size and two cases where patients experienced drug-related hepatic dysfunction. In both cases, despite the hepatotoxicity, patients’ liver function recovered rapidly upon discontinuing fenbendazole. Due to its accessibility over the counter at a relatively low price, patients have turned to fenbendazole as an at-home treatment for cancer. As the published case reports observed, the most common self-administered regimen involves taking 1 gram of fenbendazole orally once daily for three consecutive days, followed by four days off treatment. However, the use of fenbendazole for cancer therapy in humans requires further pilot and extensive clinical trials to establish effective doses and regimens. Patients with compromised liver function, liver cirrhosis, or liver cancer should use fenbendazole with caution. Additionally, combining fenbendazole with glycolysis inhibitors and hepatoprotective pharmaceutical or nutraceutical agents can lead to synergic therapeutic activity while reducing potential liver toxicity. *https://ar.iiarjournals.org/content/anticanres/44/9/3725.full.pdf

Table IV

*https://ar.iiarjournals.org/content/anticanres/44/9/3725.full.pdf

Benzimidazoles were identified from a screen that selectively targets highly metastatic prostate cancer cells but is not toxic to normal cells. We determined that the preferential antitumor activity of these agents was mediated in part through cell-cycle arrest and induction of apoptosis, both in vitro and in vivo. We further demonstrate that benzimidazole treatment prolongs the survival of mice bearing prostate cancer lung metastases and inhibits the growth of prostate cancer cells growing in the bone microenvironment. More strikingly, these anti-tumor effects remain active against prostate cancer cells that are resistant to paclitaxel, the standard chemotherapy for men with advanced prostate cancer, both in vitro and in vivo. Our study further supports the use of benzimidazoles as a potential anti-cancer therapy for men with metastatic prostate cancer.

*Benzimidazole as Novel Therapy for Hormone-Refractory Metastic Prostate Cancer, May 2011; Prepared for: The U.S. Army Medical Research and Materiel Command, Fort Detrick, Maryland 21702-5012 https://apps.dtic.mil/sti/tr/pdf/ADA545657.pdf

Often, when referring to my test results, I’ve heard the doctor say, “We’ve never seen numbers this bad.”

I’ve left a hospital “against medical advice” (AMA) on more than one occasion.

Over the past twenty-five years, I have experienced each of the steps of grief hundreds of times, never once challenging why the doctors were so certain I was about to die. Until recently, or since COVID, I had never doubted the doctor’s diagnosis.

Despite what the guys in the white coats had to say, here I am today, healthy and happy. I proved them all to be liars. Maybe you can too? You need to be prepared to say to yourself, “Thanks, but I’m strong and getting healthier every new day.”

You have to stand in front of a mirror, look yourself in the eyes, and say aloud, “I’m not going anywhere. I’m going to do my best to get better. What is my full range of options?” You need to read, learn, and try to understand how you got to this place and how to fix it. Fenbendazole is cheap, widely available, and well tested in animals. If you have cancer, Fenbendazole is definitely worth an educated try.

I’m not a doctor. Don’t read this if you want absolute medical advice from a guy wearing a white coat. I’m not a licensed professional and will never be one. This information is not medical advice. My BA from a private college does not indicate any medical school history. I’m writing to tell you that the establishment’s medical doctors don’t know everything, and the medical industry may be more interested in profits and protecting themselves from lawsuits over whether you live or die.

The Lord has the final say on your earthly existence, and you are not going anywhere if your time here on earth is not over. I urge you to seek solutions that will help you regain your health, even if they are not “recognized and approved courses of treatment.” Mimic recovery. Find people who have beaten the odds, learn how they did it, and give it a try. The graveyard will still welcome you ten or twenty years from today.

Ask yourself, why is the doctor describing your stage 4 cancer by saying “there’s nothing I can do” when simple and cheap cancer treatments such as Mebendazole, Ivermectin, or Fenbendazole are widely available for very little money? Healthy people who had stage 4 cancer and were given only months to live, have self-administered a regimen of these drugs and today are cancer-free. Not all of them, so in this blog, we will describe some of the people and how they did it. You need to learn about the tools and processes available to you now that have been shown to cure others. It didn’t cost much for these now healthy people to cure themselves of cancer. These drugs are off patent and widely available. Helpful supplements are everywhere and cost little. What is the reason doctors are not extolling these powerful treatment options?

Why were my doctors content to prescribe thousands of dollars in pills ($6,000 mo.) and treatments each month, only to focus on improving my symptoms? Why did they need thousands of dollars in monthly tests, but could never give me any idea of how to heal? The medical establishment only offered me treatment of my symptoms and the certainty that “we can’t cure you, but we can help you suffer less while you are dying.” That is bullshit.

If much of the world recognized that Fenbendazole and Mebendazole could be an absolute cure and preventative for some cancers in certain situations, why was the drug not FDA-approved to treat cancer in humans?

The answer is profit/money.

Joe Tippens’ doctor nailed the answer to this question.

He said, “probably because of money…all of these drugs are far off-patent, and nobody is going to spend a gazillion dollars to repurpose them for cancer… only to have generic competition the next day.” *https://lowtoxinforum.com/threads/alleged-cancer-cure.27459/page-4

Who is Joe? Keep reading to find out.

Why were my doctors treating symptoms rather than the cause? I wanted to recover, not just take costly pills and potions that made life easier while I died.

There was no expiration date on me. My warranty was intact, and I still had have work to do here. I would not give up, and you shouldn’t either. So keep going and prove your strength to all doubters.

Over many years and several trips to the funeral home, I realized that I did not have to believe the doctors. I followed their directions and paid for the medication. However, I decided to get better and not just be content with their diagnosis. Despite their predictions, I was not yet going to die right away from my medical issue. It has taken me years to comprehend this truth. In sharing this information, I hope to speed up your journey toward this same realization and a healthy life.

Many medical decisions appear to be influenced by financial considerations. For example, prescribing a new, expensive medication through insurance without considering more affordable, widely available options is common. If a treatment can restore health, whether a medication is FDA approved for humans but not specifically for a given illness may be less significant.

I overcame my medical issues and moved forward. You can, too. Don’t give up.

The most important thing I can share is this: You are not alone. Thousands of people like you are researching, sharing protocols, and offering information during their cancer journey. So stay positive, keep learning, and keep fighting!

I’m not a doctor. This information is not medical advice.

I’m sixty years old, and twice doctors have told me, in no uncertain terms, “You are dying. Make preparations.” Those moments changed everything, leading me to reflect and share my life here with you.

From the moment a doctor speaks, your personal journey begins. Experts say there are seven steps of grief.

1. Shock. ...

2. Denial. ...

3. Anger. ...

4. Bargaining. ...

5. Depression. ...

6. Acceptance and hope. ...

7. Processing grief.

American-Swiss psychiatrist Elisabeth Kübler-Ross first highlighted 5 stages of grief in the 1960s. Since then, her approach has been adapted and extended to 7 stages, and within that, there’s still room for debate. *https://www.hcf.com.au/health-agenda/body-mind/mental-health/moving-through-grief

Do all dying people experience these emotions in a set sequence? It’s unclear, as everyone’s journey is personal, and emotions often appear in different orders or repeat. However, speaking from experience, when you first learn of being very sick or dying, you will visit many, if not all, of the seven stages. Because of what doctors told me, I’ve been through the list twice over the past twenty-five years. I’m still here.

During this period of grief, I’ve performed morbid tasks such as selecting my coffin, had face-to-face meetings with funeral directors arranging for my burial, hired the funeral home to pick up my dead body (I live alone), and prepared all of my estate planning documentation.

When the doctor tells you that life is ending, you’ll cry about all the people you will never see again and try to predict who needs help when you are dead and gone. Each time you check into the hospital, you will wonder if yesterday was the last time you’ll see your house or your pets. You will likely start crying. You may even get angry with God for letting this happen to you. Or, try to make a bargain with the almighty that allows you to live in exchange for some promise or action. I’ve done all of these.

You may have hospice care visit your home and detail their procedure and costs for “helping you die,” or get prices on oxygen tanks for your bedroom. Hospice really sucks. It’s a mess for anyone to go through this process. I’ll never do it again for myself or anyone else.

In the United States, about 17,000 people a year are diagnosed with cancer that began in or next to the brain. These are called primary brain cancers. Another 100,000 people are diagnosed with cancer in the brain or spinal cord that spread from another place in the body. These are called secondary brain cancers.

Some brain tumors grow slowly and may become quite large before causing symptoms. Others may grow quickly and cause a sudden onset of symptoms. While most types of primary brain cancer may spread within the brain, it is rare for a primary brain tumor to spread outside the brain. Because the skull is rigid, providing no room for the tumor to expand, brain tumors may press on parts of the brain that control movement, speech, sight or other vital functions.

Even when brain tumors are benign (not cancer), they can cause serious problems. Although non-cancerous brain tumors usually grow slower than cancerous brain tumors, they may damage and press against normal brain tissue or the spine or spinal cord as they grow, potentially causing symptoms.

Brain structure and function

Emotions, thought, speech, vision, hearing, movement and many more important parts of everyday life begin in the brain. The brain sends messages throughout the body via the spinal cord and cranial nerves in the head. The network of the brain and spinal cord is called the central nervous system (CNS). Tumors can develop in the spinal cord and cranial nerves.

The hard, bony skull protects the brain, and the bones (vertebrae) of the spine protect the spinal cord. A liquid called cerebrospinal fluid surrounds both the brain and the spinal cord.

The brain has four main parts:

Cerebrum: The outer and largest part of the brain. The cerebrum has two halves that are called hemispheres. Each hemisphere has four lobes: frontal, parietal, temporal and occipital. The cerebrum is responsible for:

• Emotions

• Reasoning

• Language

• Movement of muscles

• Senses of seeing, hearing, smelling, touch

• Perception of pain

Basal ganglia: These are found deeper inside the brain. They play a part in muscle movement.

Cerebellum: This section is at the back of the brain. It helps control and coordinate movement, such as walking and swallowing.

Brainstem: The brain stem is at the base of the brain. Its nerve fibers carry messages between the cerebrum and the rest of the body. This small area is very important and even plays a part in breathing and heartbeat.

Primary Brain Tumor Types

Brain tumors are classified by the types of cells within the tumor. Each type of brain tumor grows and is treated in a different way. Most types of brain tumors are slightly more common in men than women, though meningiomas are more common in women.

Craniopharyngioma

Craniopharyngiomas are non-cancerous, slow growing tumors located near the pituitary gland. Craniopharyngioma appears primarily in children and middle-age adults. The tumor itself can be part solid and part fluid-filled cyst. Symptoms can include vision changes and slow growth caused by the tumor’s impact on the pituitary gland. These tumors primarily require treatment with specialized surgery and possibly radiation after surgery.

Dermoid cysts and epidermoid tumors

Dermoid cysts and epidermoid tumors are benign growths that arise from epithelial cells, which form the outer layer of the body and line certain organs and glands. They can develop in various parts of the body, including the central nervous system. Both are slow growing, and are often not noticed for decades. They are treated by surgical removal.

Glioma

Gliomas are a class of primary brain tumors. They are some of the fastest-growing brain tumors. The different types of gliomas include:

• Astrocytoma: Astrocytomas spread throughout the brain and mix with healthy tissue, making them difficult to treat. There are several types of astrocytoma:

  • Low-grade astrocytomas: These include grade I pilocytic astrocytoma and grade II diffuse astrocytoma. Grade I astrocytomas are rarely seen in adults.

  • Anaplastic astrocytoma: Grade III astrocytomas are known as anaplastic astrocytoma. These tumors are aggressive, high-grade cancers.

  • Glioblastoma: Grade IV astrocytomas are called glioblastoma or GBM. Glioblastoma is the most common malignant (cancerous) adult brain tumor and one of the fastest-growing tumors of the central nervous system. Learn more about glioblastoma symptoms.

• Ependymoma: Ependymomas arise from ependymal cells, which line the ventricles of the brain and the center of the spinal cord. The ventricles are chambers in the brain that produce and transport cerebrospinal fluid, which surrounds and protects the brain. Ependymomas may be found in the brain or the spine. Ependymomas are more commonly seen in children and are rare in adults.

• Oligodendroglioma: Oligodendroglioma is generally slow growing. It can be diagnosed as a grade II or grade III tumor.

Hemangioblastoma

These slow-growing tumors develop from the cells of blood vessels. A hemangioblastoma typically forms in the brainstem and cerebellum, but can appear in other locations, including the retina. About a quarter of cases are associated with von Hippel Lindau disease, a genetic condition that is tied to the development of multiple types of tumors and cancers.

Medulloblastoma

Medulloblastoma is the most common pediatric malignant brain tumor, with about 500 children diagnosed a year in the United States. In adults, medulloblastoma is a rare tumor, with about 200 diagnoses each year. Learn more on our medulloblastoma page.

Meningioma

Meningioma is the most common primary brain tumor. These tumors develop from cells in the meninges, the protective layer of tissue surrounding the brain and spinal cord. Most are benign and slow growing. Some, though, are malignant and aggressive. Surgery is usually the first treatment for meningiomas that grow and cause symptoms.

Pineal Gland Tumors

The pineal gland is located deep in the brain and makes the sleep regulating hormone melatonin. Tumors of the pineal gland can be benign or malignant. Pineal tumors include pineocytoma and pineoblastoma.

Pituitary Tumors

Pituitary tumors, also called pituitary adenomas, are usually benign (non-cancerous) growths on the pituitary gland. The pituitary gland is a key part of the endocrine system, which controls the growth and development. Learn more on our pituitary tumor page.

Sarcoma

Sarcomas are broad category of tumors that form in bones and the body’s soft tissues, including cartilage, fat, and muscle. Soft tissue sarcomas are more common than bone sarcomas. Bone sarcoma types include Ewing’s sarcoma and osteosarcoma. Some gliomas have sarcoma-like characteristics and are called gliosarcomas. Gliosarcomas behave aggressively similar to glioblastomas.

Sarcomas may also be found in the spine or skull base, including chordoma. Chordomas are rare sarcoma tumors that grow in the base of the skull and bones of the spine. Doctors believe they develop from the leftover cells that served as the framework for the skull base and spine when the patient was a developing embryo. When chordomas form in the skull, they can push into the brain and cause many of the same symptoms as brain tumors, including headaches, dizziness and confusion. Chordomas can involve multiple critical nerves and arteries, making them difficult to treat. Treatment may require the use of specialized surgery, radiation therapy and/or chemotherapy.

Primary Brain Tumor Risk Factors

Anything that increases your chance of getting a brain tumor is a risk factor. Research is ongoing into the causes and risk factors of brain tumors. While no definite risk factors have been found for brain tumors, some factors may put you at increased risk, including:

• Prior radiation exposure to the brain, often as treatment for another cancer

• Family history of certain conditions, including:

  • Neurofibromatosis type 1 and type 2

  • Tuberous sclerosis

  • von Hippel-Lindau disease

  • Li-Fraumeni syndrome

Some types of brain tumors may be passed down from one generation to the next if you have a family history of the conditions listed above. Genetic counseling may be right for you. Learn more about the risk to you and your family on our genetic testing page.

It can feel intimidating, but it doesn’t have to be. A thoughtful, respectful approach can open a productive dialogue that keeps your care team in the loop, even if they’re unfamiliar with this off-label option.

Understand What “Off-Label” Means

An off-label treatment is a drug that is FDA-approved for one condition or use (such as Fenbendazole for dogs) but is being explored for another (such as cancer support in humans).

Doctors are legally allowed to prescribe medications off-label—but they’re also expected to use discretion based on available evidence.

Do Your Homework First

Before walking into your doctor’s office, prepare:

• Research papers or articles showing Fenbendazole’s mechanisms (like its impact on microtubules or p53 gene activity).

• Success stories or case studies (while anecdotal, they can spark curiosity).

• A sample protocol or summary of how others use it alongside traditional therapies.

• A note on safety: Fenbendazole for humans is often repurposed from vet-grade sources like Safeguard Horse Dewormer, so sourcing and dosage matter.

Avoid This Approach:

“I saw this on YouTube, and I want to try it. Can you prescribe it?”

That kind of language can immediately raise red flags for your doctor. They may feel you’re asking them to support something risky or unproven. Instead, try the approach below.

Conversation Script Template

Here’s a way to open the discussion:

“I’ve been researching supportive options people are exploring alongside cancer treatments. I came across Fenbendazole, which is being looked at for its anti-parasitic and potential anti-cancer effects. I understand it’s off-label, but I wanted to ask your thoughts and make sure I’m being safe if I choose to explore it on my own.”

You’ve done three things here:

1. Expressed curiosity, not defiance.

2. Acknowledged their expertise.

3. Created space for honest input.

Expect These Common Responses

1. “There’s no clinical data.” This is fair—and true. You can respond with:

“I understand the data is early. I’m simply trying to build the best environment for healing and wanted to bring it to your attention in case it interacts with other treatments.”

2. “I can’t recommend this.” No problem. Thank them for their input, and let them know you’ll proceed cautiously and keep them updated.

3. “I’ve actually heard about this…” Some practitioners are already aware of Fenbendazole for cancer support. This could lead to a deeper conversation.

Be Honest and Collaborative

Doctors may not be thrilled by anything outside the medical playbook—but many respect patients who take ownership of their health and remain transparent.

Let them know if you’re combining Fenbendazole with other supplements or medications, and ask if they see any red flags with your plan.

Final Takeaways:

• Off-label doesn’t mean unsafe, but it does require careful research and communication.

• Show your doctor you value their role in your journey.

• Avoid demanding approval—seek collaboration instead.

• Keep your mindset open, grounded, and proactive.